Geneva, Aug. 31 -- International Clinical Trials Registry received information related to the study (NCT07777120) titled 'Liso-Cel in Relapsed/Refractory Marginal Zone Lymphoma' on Aug. 18.

Study Type: Observational

Primary Sponsor: Bristol-Myers Squibb

Condition: Marginal Zone Lymphoma

Intervention: Biological: lisocabtagene maraleucel

Recruitment Status: Not recruiting

Date of First Enrollment: March 24, 2026

Target Sample Size: 300

Countries of Recruitment: United States

To know more, visit https://clinicaltrials.gov/study/NCT07777120

Disclaimer: Curated by HT Syndication....